ElmediX
ElmediX is a Belgian medtech company developing whole-body thermal therapy at 41.5°C as an adjunct cancer treatment, primarily targeting pancreatic cancer. Founded in 2015 as a University of Antwerp spin-off, it serves healthcare providers and hospitals through its proprietary medical device.
- Company typePrivate
- Founded2015
- HeadquartersMechelen, Belgium
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ElmediX does
ElmediX is a Belgian medtech company developing a proprietary whole-body thermal therapy (hyperthermia) system as an adjunct cancer treatment. Founded in 2015 as a spin-off of the University of Antwerp by Prof. dr. John-Paul Bogers (CEO) and Ir. Johan Van den Bossche (Chairman), the company targets a core clinical problem: the limited treatment options for pancreatic cancer and other hard-to-treat metastatic cancers. The ElmediX device raises a patient's body temperature to 41.5°C in a controlled, stable manner using innovative temperature sensor technology, delivered under anesthesia in up to three sessions of 2–8 hours each. The mechanism is intended to enhance chemotherapy absorption, increase cancer cells' sensitivity to radiation (1.5–5x), activate the immune system, and directly induce tumor cell death through necrosis and apoptosis.
The technology platform is anchored by 8 patent families granted in the EU, USA, China, and Hong Kong, supplemented by registered ElmediX® trademarks in the same jurisdictions. Beyond the core therapeutic device, ElmediX has launched research tools: a Precision Egg Incubator (2023) for in-ovo tumor studies and a Phantom Thermal Simulator (2024) for human-body-mimicking research and training, both deployed at research institutions in Belgium, France, and Italy. The company operates from Leuven and Mechelen in Belgium and a New York office, supporting a planned US market entry.
ElmediX is pre-commercial: revenue is not publicly disclosed, pricing is not listed, and there are no paying commercial customers. The intended business model combines future hardware sales of the thermal therapy device to hospitals and oncology centers, treatment services delivered through partner institutions, and potential licensing of patented technology. GTM is enterprise-field-sales oriented, targeting oncologists, hospitals, and cancer treatment centers rather than direct-to-consumer channels. The company successfully completed its MATTERS First-In-Human clinical trial in 2025 and is planning the MATTERS-2 multicenter efficacy trial for 2026, positioning it for the next stage of clinical evidence generation and eventual commercialization.
ElmediX firmographics
Firmographics- Name
- ElmediX
- Legal name
- ElmediX NV
- Website
- https://elmedix.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ElmediX is a Belgian medtech company developing whole-body thermal therapy at 41.5°C as an adjunct cancer treatment, primarily targeting pancreatic cancer. Founded in 2015 as a University of Antwerp spin-off, it serves healthcare providers and hospitals through its proprietary medical device.
- Ownership category
- akta.pro rank
ElmediX industry classification
Industry- Product category
- Cancer Treatment Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Medical Oncology (HLAKAFAB)
- akta.pro secondary industries
- Radiation Oncology (HLAKAFAC), Gastrointestinal Oncology (HLAKAFAK)
Keywords
Where ElmediX is headquartered
LocationHeadquarters
- HQ city
- Mechelen
- HQ country
- Belgium
- HQ region
- Europe
Offices3 records
Markets served
ElmediX business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Medical Device Sales: Future commercialization of thermal therapy medical devices to hospitals and healthcare facilities. The company is developing a treatment device that will be sold to healthcare institutions.
- Clinical Treatment Services: Treatment delivery services through partnered hospitals and oncology centers where the thermal therapy is administered to patients.
- Technology Licensing: Potential licensing of patented thermal therapy technology to other medical device companies or healthcare institutions.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
ElmediX product offering
Product offeringCore offering
ElmediX develops and is commercializing a proprietary whole-body thermal therapy medical device that raises a patient's body temperature to 41.5°C in a controlled manner as an adjunct anti-cancer treatment. The therapy is administered in up to 3 sessions of 2-8 hours each under anesthesia, enhancing the efficacy of chemotherapy and radiotherapy and stimulating immune response. The product is targeted at hospitals, oncology centers, and healthcare providers for treating cancer patients, primarily those with pancreatic cancer.
Product overview
ElmediX is a medtech company offering a thermal therapy treatment system for cancer patients. The core product is the Thermal Therapy (Whole-Body Thermal Treatment) system, which raises body temperature to 41.5°C using a proprietary medical device with innovative temperature sensor technology. This is complemented by research tools including the Phantom Thermal Simulator (human body-mimicking phantom for training) and Precision Egg Incubator (for in-ovo research). The treatment is designed as an adjunct to chemotherapy and radiotherapy, enhancing their effectiveness by stimulating the immune system, directly killing cancer cells, and increasing drug absorption. The company completed its First-In-Human MATTERS clinical trial in 2025 and is planning the multi-center MATTERS-2 efficacy trial.
Differentiator
Problem solved
Functional benefit
Products and services
- Thermal Therapy (Whole-Body Thermal Treatment)
Quantifiable outcome
- Progression-free survival increased from 4.9 to 8.8 months with thermal therapy added to chemoradiotherapy (Ohguri et al, 2008)
- +3 more outcomes
Companies that use ElmediX
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
ElmediX technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
ElmediX partnerships and signals
Strategic signalScale indicators5 records
Recent moves7 records
Expansion highlights5 records
ElmediX competitors and assessment
Company assessmentDirect peers
- Pyrexar Medical (formerly BSD Medical): A US-based hyperthermia device manufacturer offering systems for localized, regional, and whole-body hyperthermia used adjunctively with chemotherapy and radiation. Pyrexar is the closest direct peer to ElmediX, competing in the same oncology hyperthermia niche.
- Celsius42 GmbH: A German medical technology company specializing in whole-body and localized hyperthermia systems for cancer treatment. Celsius42 competes directly with ElmediX in the European oncology hyperthermia market.
- Oncotherm: A Hungarian company developing and commercializing oncological hyperthermia devices (modulated electro-hyperthermia) used in combination with conventional cancer therapies. Oncotherm is a direct peer in the cancer hyperthermia equipment category.
- Med-Logix: A European distributor and developer of hyperthermia systems used in oncology treatment. Med-Logix is comparable as a channel and equipment player in the same cancer hyperthermia category as ElmediX.
- Andromedic: A Spanish medical technology company providing hyperthermia devices for cancer treatment in European and Latin American markets. Andromedic is comparable as a regional peer offering whole-body and localized hyperthermia equipment.
- MagForce: A German medical technology company developing NanoTherm therapy, a minimally invasive, focal tumor ablation technique using magnetic nanoparticles. MagForce is comparable as a European medtech peer pursuing novel physics-based cancer therapies, including glioblastoma, with a similar clinical-development-stage profile.
Broad incumbents
- Varian Medical Systems (Siemens Healthineers): A global leader in radiation oncology equipment and software, now part of Siemens Healthineers. Varian is comparable as a broad incumbent serving the same oncology customer base that ElmediX targets, with thermal therapy positioned as complementary to its radiotherapy portfolio.
- Elekta: A Swedish-based global provider of radiation therapy, radiosurgery, and related oncology equipment and software. Elekta is a broad incumbent peer because its linear accelerators and brachytherapy systems are used by the same hospitals that would adopt ElmediX's adjunctive thermal therapy.
- Accuray: A US-based radiation oncology equipment company (CyberKnife, TomoTherapy). Accuray serves the same radiation oncology customers that ElmediX targets and represents a potential strategic partner or competitor depending on how thermal adjunctive therapy is positioned.
Emerging players
- ViewRay: A US-based medical device company developing MR-guided radiation therapy systems. ViewRay is comparable as an emerging oncology technology player targeting similar hospital customers with novel, integrated treatment modalities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
ElmediX social profiles
Digital presenceElmediX financial estimates
Financial estimateRevenue estimate
Valuation estimate
ElmediX leadership team
Management profileNumber of profiles
Profiles5 records
ElmediX funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ElmediX M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ElmediX
What does ElmediX do?
ElmediX develops and is commercializing a proprietary whole-body thermal therapy medical device that raises a patient's body temperature to 41.5°C in a controlled manner as an adjunct anti-cancer treatment. The therapy is administered in up to 3 sessions of 2-8 hours each under anesthesia, enhancing the efficacy of chemotherapy and radiotherapy and stimulating immune response. The product is targeted at hospitals, oncology centers, and healthcare providers for treating cancer patients, primarily those with pancreatic cancer.
Is ElmediX a public or private company?
ElmediX is a private company. It is classified as venture growth investor backed and is currently operating.
When was ElmediX founded?
ElmediX was founded in 2015. It employs 11 to 50 people.
Where is ElmediX based?
ElmediX is headquartered in Mechelen, Belgium, in the Europe region.
How does ElmediX make money?
Three revenue lines are on record. Medical Device Sales are the primary driver. The others are clinical Treatment Services and technology Licensing.
Who are ElmediX's main competitors?
Direct peers on record are Pyrexar Medical (formerly BSD Medical), Celsius42 GmbH, Oncotherm, Med-Logix, Andromedic and MagForce. Broad incumbents are Varian Medical Systems (Siemens Healthineers), Elekta and Accuray. ViewRay is listed as an emerging player.
Does ElmediX have an API?
No public API is recorded for ElmediX.
What industry is ElmediX in?
ElmediX's product category is Cancer Treatment Medical Devices. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology, with a secondary code of HLAKAFAC, Radiation Oncology. Its NAICS code is 334510 and its SIC code is 3845.